Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Multivariate analysis including all patients (n = 44,498)

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  Hazard Ratio 95% Confidence Interval p-value
Sex Male 1.00 Ref < 0.0001
Female 0.82 0.80–0.84
Age 18–59 1.00 Ref < 0.0001
60–69 1.02 .099–1.05
70–79 1.05 1.02–1.08
80+ 1.15 1.10–1.20
Comorbidity 0 1.00 Ref < 0.0001
1 1.08 1.05–1.10
> 2 1.23 1.19–1.28
Histology Adenocarcinoma 1.00 Ref < 0.0001
Non-adenocarcinoma 1.14 1.12–1.16
Race White 1.00 Ref < 0.0001
Non-white 0.88 0.85–0.91
Insurance Uninsured 1.00 Ref 0.012
Insured 0.92 0.88–0.98
Facility Type Academic 1.00 Ref < 0.0001
Nonacademic 1.16 1.13–1.18
Systemic Therapy Chemotherapy 1.00 Ref < 0.0001
Immunotherapy 0.81 0.78–0.84
Radiation No Radiation 1.00 Ref < 0.0001
EBRT 1.16 1.13–1.18
SRT 0.73 0.69–0.78